ClearPoint Neuro
  • Home
  • Company
    • Overview
    • Industry Partners
    • Board of Directors
    • Management Team
    • Biologics & Drug Delivery Team
    • Academic Relationships
    • Manufacturing & Assembly
    • Intellectual Property
    • Healthcare Compliance
    • Research Projects
      • ClearTrace
    • Newsletters
    • ClearPoint TV Webinars
  • Products
    • ClearPoint® System
      • ClearPoint System Overview
      • ClearPoint Reimbursement Guide
      • ClearPoint Applications
      • ClearPoint Demonstration Video
      • System Products
      • ClearPoint Bibliography
      • ClearPoint System Locations
    • MRI-Guided Drug Delivery
      • MRI-Guided Drug Delivery
      • SmartFlow® Product Sheet
    • TRANBERG® Thermal Therapy System
  • Investors
    • Overview
      • Overview
    • Company Information
      • Profile
      • Management Team
    • News / Events / Presentations
      • Press Releases
      • ClearPoint In The News
      • Events
      • Investor Presentations
    • Stock Information
      • Quote
      • Charts
      • Historical Quotes
      • Analyst Coverage
    • SEC Filings
      • All SEC Filings
    • Corporate Governance
      • Board of Directors
      • Board Committees
      • Governance Documents
    • Investor Resources
      • FAQ
      • IR Contacts
      • Email Alerts
  • Careers
  • Contact
    • Irvine, CA
    • Academic Materials Request
    • Program Coordinator Kit Request

Site Info

  • Home
  • Careers
  • Privacy Policy
  • Terms of Use
  • Disclaimer
  • Sitemap
  • Contact Us

  • Home
  • » Site Info

Site Info

Site Info

  • Home
  • Careers
  • Privacy Policy
  • Terms of Use
  • Disclaimer
  • Sitemap
  • Contact Us

Investor Quick Links

  • Overview
  • IR Contacts
  • IR FAQ
  • News/Events
  • SEC Filing
  • Corporate Governance

Recent News

  • Apr 13, 2021
    ClearPoint Neuro, Inc. Announces Retirement of Director John N. Spencer, Jr.
  • Apr 6, 2021
    ClearPoint Neuro, Inc. Congratulates uniQure on Completion of Enrollment in First Cohort of Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease
  • Mar 24, 2021
    ClearPoint Neuro, Inc. Announces Appointment of Ellisa Cholapranee as General Counsel

© Copyright 2021 ClearPoint Neuro, Inc.
Website by Equisolve